Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- 60% Generic Share Target Is Highly Achievable: Daiichi Sankyo Espha President Yoshiwaka
July 19, 2013
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
- Cancer, CNS Diseases to Be Important Fields for MSD Over Next 10 Years: Pres. Alvarez
July 12, 2013
- Anti-HIV Treatment Prezista Naive Tablet 800 mg Approved: Janssen
July 12, 2013
- Daiichi Sankyo Voluntarily Recalls Mevalotin Granules 1% Due to Contamination with Vitamin Capsule
July 12, 2013
- Empagliflozin Alone Lowers Blood Glucose Level: BI, Eli Lilly
July 11, 2013
- Sanofi Begins Domestic PII Study of Vaccine Against CDIs
July 11, 2013
- Mediceo’s New Tokyo Logistics Center Completed, Operations to Start in September
July 11, 2013
- Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
- Sumitomo Bakelite Files Application for Gene Chip for Cancer Diagnosis
July 11, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…